Skip to main content
Delfa

← All assets

Xanomeline / trospium

10 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

10

Ongoing

10

Recruiting

10

Completed

0

Sites

1,326

Countries

36

Endpoints

177

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 177 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 3
10

Trials by status

Recruiting
10

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Other (unclassified)
82
Safety / tolerability / PK
43
Behavior / neuropsychiatric
36
Global cognition
7
Other clinical outcomes
5
Function / daily living
2
Caregiver / quality of life
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 34 of 177 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

23

Mini-Mental State Examination (MMSE)Cognition

4

ADAS-CogCognition

3

ADAS-CogOther

2

ADCS-Activities of Daily Living (ADCS-ADL)Function

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

10 of 10

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Xanomeline / trospium

Alzheimer’s disease

Age 55-90Ph 3Recruiting429Sep 2027-
NCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Xanomeline / trospium

Alzheimer’s disease

Alzheimer's diseasePh 3Recruiting292Nov 2026-
NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Xanomeline, Xanomeline / trospium

Alzheimer’s disease

Study partner/caregiver requiredPh 3Recruiting256Jun 2029-
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Xanomeline, Xanomeline / trospium

Alzheimer’s disease

Alzheimer's diseasePh 3Recruiting158Nov 2028-
NCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Xanomeline / trospium

Alzheimer’s disease

Alzheimer's diseasePh 3Recruiting154Dec 2026-
NCT07011745A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Xanomeline, Xanomeline / trospium

Alzheimer’s disease

Alzheimer's diseasePh 3Recruiting145Nov 2028-
NCT05511363A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Xanomeline / trospium

Alzheimer’s disease

Alzheimer's diseasePh 3Recruiting129Oct 2026-
MINDSET 2A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Xanomeline, Xanomeline / trospium

Alzheimer’s disease

Alzheimer's diseasePh 3Recruiting126Sep 2028-
MINDSET 1A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Xanomeline, Xanomeline / trospium

Alzheimer’s disease

Alzheimer's diseasePh 3Recruiting116Sep 2028-
NCT06947941A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Xanomeline, Xanomeline / trospium

Alzheimer’s disease

Alzheimer's diseasePh 3Recruiting22Feb 2028-

Showing 1-10 of 10 trials